- Universal Biosensors (UBI) has appointed John Sharman as the new Chief Executive Officer
- John has over 20 years experience and just yesterday announced his resignation as CEO of Medical Developments International
- The soon-to-be UBI CEO stated he wanted to pursue new business interests
- John will begin his new role no later than July 4th 2020
- Universal Biosensors is up 30 per cent and selling shares for 19.5 cents apiece
Universal Biosensors (UBI) has appointed John Sharman as the new Chief Executive Officer.
John has over 20 years experience and has recently resigned as CEO of Medical Developments International (MVP) citing he wanted to pursue new “business interests”.
During his 10 years at MVP, he oversaw the development of the business into a successful global pharmaceutical and medical device company. He also saw an increased shareholder value from $7 million to over $700 million.
John holds a Bachelor of Economics from Monash University and a Master of Applied Finance from Macquarie University.
He will begin his new role no later than July 4 which is when his role terminates at MVP. Part of his resignation included staying in the role for a period of three months to assist with finding a suitable replacement.
“I am very excited to join UBI as CEO,” John told the market.
“Universal has a number of real and valuable business opportunities and I am looking forward to working with the Chairman, Board and management team to deliver those opportunities and to create significant shareholder value,” he added.
Non-Executive Chairman, Craig Coleman said he is thrilled to appoint John as the CEO and believes he is a great fit for the company.
“His appointment and leadership positions the company to now realise the full potential of our products and services, technology and cash reserves,” Craig said.
“John’s experience and relationships will enhance our organic growth opportunities, including the existing coagulation testing products and recently announced Free Sulfur Dioxide wine testing platform,” he added.
Universal Biosensors is up 30 per cent on the market, selling shares for 19.5¢ apiece at market close.